Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Implantable Drug Firm Valera Gets $11.5M In Third Round

Aug. 23, 2004

By Aaron Lorenzo

ProlX In-Licenses Class Of Early Stage Cancer Drugs

Aug. 20, 2004

By Aaron Lorenzo

ProlX In-Licenses Class Of Early Stage Cancer Drugs

Aug. 20, 2004

By Aaron Lorenzo

CyDex Series B Nets $17M For Internal Drug Programs

Aug. 18, 2004

By Aaron Lorenzo

CyDex Series B Nets $17M For Internal Drug Programs

Aug. 18, 2004

By Aaron Lorenzo

Using Bacteria As Therapeutic, Osel Advancing Lead Product

Aug. 17, 2004

By Aaron Lorenzo

Ciphergen Test Shows Promise For Detection Of Ovarian Cancer

Aug. 17, 2004

By Aaron Lorenzo

Ciphergen Test Shows Promise For Detection Of Ovarian Cancer

Aug. 17, 2004

By Aaron Lorenzo

Using Bacteria As Therapeutic, Osel Advancing Lead Product

Aug. 17, 2004

By Aaron Lorenzo

Spectrum Deals For Rights To Clinical-Stage LHRH Antagonist

Aug. 13, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...